Completed
Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)
A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Telcagepant (MK-0974) for Prevention of Menstrually Related Migraine in Female Patients With Episodic Migraine
- Status
- Completed
- Registry ID
- NCT01125774
- Type
- Interventional (tests a treatment)
- Phase
- Phase 2, Phase 3
- Conditions
- Migraine
- What is tested
- Telcagepant (drug); Placebo (drug)
- Sponsor
- Merck Sharp & Dohme LLC
- Participants
- 4548
- Start
- 2010-06-01
- Completion
- 2011-04-08
- Last update
- 2018-10-23
- Results posted
- Yes
About the study
This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period. This study will also evaluate the safety and tolerability of telcagepant for female migraine participants.
Summary from ClinicalTrials.gov.